Charles River Laboratories International, Inc.
CRL
株式のランク
#1357
Charles River Laboratories International, Inc. operates as a contract research... Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
株価
$340.31
時価総額
$16.39B
変化（1日）
7.29%
変化（1年）
80.77%
国
US
取引 Charles River Laboratories International, Inc. (CRL)
カテゴリー
Healthcare
Charles River Laboratories International, Inc.（CRL）の収益
Jun 2026 時点の収益 TTM: $4.00B
Charles River Laboratories International, Inc. の最新の財務報告によると、現在の収益 (TTM) は $4.00B です。2023 年には $4.13B の収益があり、これは 2022 年の $3.98B と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Charles River Laboratories International, Inc. の収益履歴（2000 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $4.00B | -1.26% |
| 2024 | $4.05B | -1.92% |
| 2023 | $4.13B | 3.86% |
| 2022 | $3.98B | 12.31% |
| 2021 | $3.54B | 21.08% |
| 2020 | $2.92B | 11.55% |
| 2019 | $2.62B | 15.67% |
| 2018 | $2.27B | 21.99% |
| 2017 | $1.86B | 10.48% |
| 2016 | $1.68B | 23.34% |
| 2015 | $1.36B | 5.06% |
| 2014 | $1.30B | 11.34% |
| 2013 | $1.17B | 3.19% |
| 2012 | $1.13B | -1.15% |
| 2011 | $1.14B | 0.81% |
| 2010 | $1.13B | -5.75% |
| 2009 | $1.20B | -10.49% |
| 2008 | $1.34B | 9.17% |
| 2007 | $1.23B | 16.27% |
| 2006 | $1.06B | -5.69% |
| 2005 | $1.12B | 46.33% |
| 2004 | $766.92M | 24.96% |
| 2003 | $613.72M | 10.65% |
| 2002 | $554.63M | 19.11% |
| 2001 | $465.63M | 51.88% |
| 2000 | $306.59M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $46.34B | 1,058.69% |
US
|
|
| $25.11B | 527.83% |
US
|
|
| $2.71B | -32.31% |
US
|
|
| - | - |
CN
|
|
| $7.37B | 84.35% |
US
|
